New drug duo targets stubborn blood cancer
NCT ID NCT02940301
Summary
This study is testing whether combining two existing cancer drugs—ibrutinib (a pill) and nivolumab (an IV infusion)—can help people with Hodgkin's lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if this combination can shrink tumors and keep the cancer under control. The trial is for adults who have already tried at least one other treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Winship Cancer Center of Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.